If you have been watching television or searching online for news lately, then you have likely heard about the recall of Zantac along with is generic name, Ranitidine. In addition to the recall, there have even been Zantac lawsuit investigation actions in the news due to the nature of the recall. The following information will help you understand when ranitidine was recalled, why it was recalled, and which types of ranitidine were recalled.
If you believe you have been impacted after taking Zantac, please contact professional Zantac lawsuit lawyers today. You may be eligible for a Zantac lawsuit investigation. Our professional Zantac lawsuit lawyers at Shamis & Gentile, P.A are here to help you receive the entitlement you deserve.
Which Kinds of Ranitidine Have Been Recalled?
In September of 2019, the FDA released a statement indicating that some batches of ranitidine medications, including Zantac, may have been contaminated with NDMA. NDMA is considered a known carcinogen which may cause an increased risk in cancers and other health problems. After the September 2019 announcement, some companies and drug makers voluntarily recalled their ranitidine products; this included some manufacturers which supplied ranitidine drugs to pharmacies at Walmart, Rite Aid, Walgreens and CVS.
These recalls included:
- Ranitidine hydrochloride capsules produced by Sandoz (September 23, 2019)
- Apotex ranitidine tablets (September 25, 2019)
- Sanofi Zantac tablets over the counter (October 18, 2019)
- Reddy’s ranitidine tablets (October 23, 2019)
- Perrigo ranitidine products, including store-brand names (Equate/Walmart, Walgreens, Member’s Mark/Sam’s Club, CVS, and Kroger) (October 23, 2019)
- Novitum Pharma ranitidine capsules (October 25, 2019)
- Lannett Companyr ranitidine syrup (October 25, 2019)
- Aurobindo Pharma ranitidine tablets, syrups and capsules (November 6, 2019)
- Amneal Pharmaceuticals ranitidine syrup and tablets (November 8, 2019)
- Golden State Medical Supply ranitidine capsules (November 15, 2019)
- Precision Dose ranitidine oral solution (November 19, 2020)
- Glenmark pharmaceuticals ranitidine capsules (December 17, 2019)
- Denton Pharmaceuticasl ranitidine tablets (January 6, 2020)
- Appco Pharmaceuticals ranitidine tablets (January 7, 2020)
- American Health Packaging ranitidine tablets (February 27, 2020)
Finally, on April 1st, 2020, the FDA requested that all ranitidine products–over the counter and prescription–be recalled.
Why Were Ranitidine Medications Recalled?
Ranitidine products were recalled due to multiple tests confirming the presence of high levels of NDMA in ranitidine products. NDMA is classified as a probable human carcinogen, and its presence in products is highly regulated due to the negative impact it can have on someone’s health.
The acceptable daily intake level of NDMA is 96 nanograms er day; these studies found that ranitidine tablets contained much more than the daily recommended intake. In addition to finding high levels of NDMA in ranitidine products, a study by Emery Pharma also found that the level of NDMA in ranitidine rose even if the drug was kept at room temperature; and rose quickly if the product was exposed to higher temperatures. Ron Najafi noted that “in this case [NDMA] … is not an impurity in the drug; it’s being formed from the drug itself.”
Is Ranitidine Associated with a Higher Cancer Risk?
It is possible that regular users of ranitidine medications, including Zantac, may have been exposed to high levels of NDMA. Higher levels of NDMA exposure are associated with an increased risk for certain cancers, including gastric, colorectal and liver cancers.
You may be eligible to participate in a Zantac lawsuit investigation if you regularly used ranitidine, including the brand name Zantac, and were later diagnosed with one or more types of cancer.
Contact Zantac Lawsuit Lawyers Today
If you believe you are eligible for a Zantac lawsuit investigation, then please contact your Zantac Lawyers, Shamis & Gentile, P.A. for a free case review. We can be contacted via email at info@shamisgentile.com or contacted via phone at 305-479-2299.
